The research, funded by the NZ Health Research Council and now published by Nature in Scientific Reports, found that patients with anxiety disorders had high conflict rhythmicity that differed in its extent across diagnoses.
Those with high scores represent a specific kind of anxiety disorder, which will be more likely to respond to specific anti-anxiety drugs. However, those with particularly extreme scores will be resistant to conventional treatment.
Professor McNaughton says the biomarker is based on a theory that has been evolving for more than 50 years.
It is an important break-through as current psychiatric diagnoses use symptoms (e.g. cough) not causes (e.g. SARS-CoV-2), so there are no clear targets for therapy, and current treatments, both drugs and psychological, have low response rates.
The new biomarker can help develop new diagnostic tests and treatments for anxiety disorders, meaning patients will achieve remission faster and with a less hit-and-miss choice of treatments, he says.
“Our biomarker provides an immediate foundation for the development of new drugs and for diagnostic tests that could guide treatment choice and so improve response rates.”
In the longer term, the underlying theory of the research should also allow similar advances across the range of threat and stress-related disorders.
Better treatment for anxiety disorders will help reduce the burden on patients, their families, workplaces, and governments through reduced health costs, Professor McNaughton says.
Source: Eurekalert
